Related Experiment Video

Updated: Aug 19, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Diabetes outfoxed by GLP-1?

George G Holz1, Oleg G Chepurny

  • 1Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA. holzg01@popmail.med.nyu.edu <holzg01@popmail.med.nyu.edu>

Science'S STKE : Signal Transduction Knowledge Environment
|January 27, 2005
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) signaling in pancreatic beta cells promotes Foxo1 nuclear exclusion via protein kinase B (PKB). This mechanism may enhance beta-cell function and insulin secretion, benefiting type 2 diabetes.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Cell Signaling

Background:

  • Foxo1 transcription factor activity is regulated by insulin/IGF-1 signaling pathways in pancreatic beta cells.
  • Phosphorylation of Foxo1 by protein kinase B (PKB) leads to nuclear exclusion and altered gene expression impacting cell growth.
  • The role of G protein-coupled receptors (GPCRs) in regulating Foxo1 activity via PI3K/PKB pathways is under investigation.

Purpose of the Study:

  • To investigate whether GPCRs, specifically for GLP-1, regulate Foxo1 activity in pancreatic beta cells.
  • To elucidate the signaling mechanisms by which GLP-1 influences Foxo1, PI3K, and PKB.
  • To understand how GLP-1 signaling contributes to beta-cell mass, insulin secretion, and glucose-lowering effects.

Main Methods:

  • Analysis of GLP-1 receptor activation effects on IRS-2, PI3K, and PKB in beta cells.
  • Investigating the role of PKB in mediating GLP-1-induced Foxo1 nuclear exclusion.
  • Review of signaling properties of GLP-1 relevant to beta-cell function and glucose homeostasis.

Main Results:

  • GLP-1 receptor activation significantly alters IRS-2, PI3K, and PKB activity in beta cells.
  • GLP-1 promotes Foxo1 nuclear exclusion through a PKB-dependent mechanism.
  • This pathway may lead to increased expression of PDX-1, a key regulator of beta-cell growth.

Conclusions:

  • GLP-1 signaling pathway, involving PKB and Foxo1, is crucial for beta-cell function.
  • GLP-1's ability to increase beta-cell mass and insulin secretion may be mediated by Foxo1 nuclear exclusion.
  • Understanding this mechanism offers insights into therapeutic strategies for type 2 diabetes.

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...